| Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes E Bernard, Y Nannya, RP Hasserjian, SM Devlin, H Tuechler, ... Nature medicine 26 (10), 1549-1556, 2020 | 532 | 2020 |
| Molecular international prognostic scoring system for myelodysplastic syndromes E Bernard, H Tuechler, PL Greenberg, RP Hasserjian, JE Arango Ossa, ... NEJM evidence 1 (7), EVIDoa2200008, 2022 | 530 | 2022 |
| ZBTB33 Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing EM Beauchamp, M Leventhal, E Bernard, ER Hoppe, G Todisco, ... Blood cancer discovery 2 (5), 500-517, 2021 | 28 | 2021 |
| Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms G Todisco, M Creignou, A Gallì, P Guglielmelli, E Rumi, M Roncador, ... Leukemia 35 (8), 2371-2381, 2021 | 27 | 2021 |
| Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era–a report from the Swedish CML register S Söderlund, T Dahlén, F Sandin, U Olsson‐Strömberg, M Creignou, ... European journal of haematology 98 (1), 57-66, 2017 | 25 | 2017 |
| TP53 state dictates genome stability, clinical presentation and outcomes in myelodysplastic syndromes E Bernard, Y Nannya, T Yoshizato, RP Hasserjian, R Saiki, Y Shiozawa, ... Blood 134, 675, 2019 | 22 | 2019 |
| Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+ 1 B-cell maturation antigen (BCMA)× CD3 T-cell engager (TCE), administered subcutaneously (SC) in patients (Pts) with relapsed … N Bar, MV Mateos, P Ribas, M Hansson, L Paris, CC Hofmeister, ... Blood 142, 2011, 2023 | 21 | 2023 |
| Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms Y Nannya, M Tobiasson, S Sato, E Bernard, S Ohtake, J Takeda, ... Blood Advances 7 (14), 3624-3636, 2023 | 19 | 2023 |
| Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: clinical and molecular genetic prognostic factors in a Nordic population E Wedge, JW Hansen, I Dybedal, M Creignou, E Ejerblad, F Lorenz, ... Transplantation and cellular therapy 27 (12), 991. e1-991. e9, 2021 | 12 | 2021 |
| Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes M Sirenko, E Bernard, M Creignou, D Domenico, A Farina, ... Blood 144 (11), 1221-1229, 2024 | 10 | 2024 |
| P883: Alnuctamab (ALNUC; BMS-986349; CC-93269), A BCMA× CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Latest results from a phase 1 … SW Wong, N Bar, MV Mateos, P Ribas, M Hansson, L Paris, C Hofmeister, ... Hemasphere 7 (S3), e1220745, 2023 | 10 | 2023 |
| Molecular taxonomy of myelodysplastic syndromes and its clinical implications E Bernard, RP Hasserjian, PL Greenberg, JE Arango Ossa, M Creignou, ... Blood 144 (15), 1617-1632, 2024 | 9 | 2024 |
| Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study C Lindholm, E Olofsson, M Creignou, L Nilsson, HG Garelius, ... Bone Marrow Transplantation 57 (4), 598-606, 2022 | 9 | 2022 |
| Clinical impacts of germline DDX41 mutations on myeloid neoplasms H Makishima, Y Nannya, J Takeda, Y Momozawa, R Saiki, T Yoshizato, ... Blood 136, 38-40, 2020 | 8 | 2020 |
| Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes E Bernard, Y Nannya, RP Hasserjian, SM Devlin, H Tuechler, ... Nature medicine 27 (5), 927-927, 2021 | 6 | 2021 |
| Two cases of VEXAS syndrome K Gunnarsson, B Tesi, M Tobiasson, M Creignou, J Ungerstedt Lakartidningen 119, 22024-22024, 2022 | 5 | 2022 |
| Der (1; 7)(q10; p10) presents with a unique genetic profile and frequent ETNK1 mutations in myeloid neoplasms R Okuda, Y Nannya, Y Ochi, M Creignou, H Makishima, T Yoshizato, ... Blood 138, 1513, 2021 | 5 | 2021 |
| Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts PL Moura, T Mortera-Blanco, IJ Hofman, G Todisco, WW Kretzschmar, ... Cancer Research 84 (2), 211-225, 2024 | 4 | 2024 |
| Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) A Spencer, KF Iversen, B Dhakal, M Creignou, J Chen, IH Hiemstra, ... Blood 140 (Supplement 1), 7320-7321, 2022 | 4 | 2022 |
| Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts G Todisco, M Creignou, E Bernard, AC Björklund, PL Moura, B Tesi, ... Clinical Cancer Research 29 (20), 4256-4267, 2023 | 3 | 2023 |
